Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis

Abstract

This analysis confirms the repeatability of results from the RCT on safety and efficacy of rifaximin 550 mg twice daily in reducing the risk of hepatic encephalopathy recurrence, and suggests these findings are translatable outside of a rigorous, controlled trial setting.